Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §3

Thymalin — clinical evidence

Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.

Document identifier
CEI-MN-041/3
Series
Compound monograph
Version
4.1
Published
15 Oct 2025
Last reviewed
15 Jul 2026
Next review
15 Jul 2028
Identifier
10.71829/cei.mono.41
Certainty
Very low
Cycle
2025 Q4

§3Clinical evidence

Assessed outcomes for ThymalinPoint estimates with confidence intervals for each contributing study, plotted against the line of no effect.0.00.20.40.60.8Standardised direction and relative magnitude of the recorded effectIndicationEffect as recordedAgeing0 trials · Very lowNo assessable evidence identifiedImmune modulation1 trial · Very lowRussian clinical reports describe…
Moderate or high certaintyLow or very low certainty
Figure 3. Illustrative. Assessed outcomes plotted on a common standardised axis so that direction and relative magnitude can be compared at a glance. The estimates are not on a common natural scale and the intervals are the Institute's standardised representation of the reported precision, not the published confidence intervals. Published intervals appear in the per-indication extracts and in the text below.

§3.1Biological ageing and healthspan endpoints

Anchor outcome. Epigenetic age acceleration.

Effect as recorded. No assessable evidence identified; —.[1,2]

Certainty. Very low certainty —

Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.

Full evidence extract for biological ageing and healthspan endpoints · Indication assessment

§3.2Immune modulation and adjunctive immunotherapy

Anchor outcome. CD4 and CD8 counts.

Effect as recorded. Russian clinical reports describe immunological and clinical effects across a wide range of conditions; not extractable to the Institute's standard.[2,3]

Certainty. Very low certainty For a substance of undefined composition, the Institute cannot in principle assign a certainty rating above very low, because the intervention itself is not specified.

Contributing trials. THYMALIN-RU-1. Full structured abstracts are published for each.

Full evidence extract for immune modulation and adjunctive immunotherapy · Indication assessment

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. United States Pharmacopeial Convention. General Chapter ⟨85⟩ Bacterial Endotoxins Test. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
  2. United States Pharmacopeial Convention. General Chapter ⟨71⟩ Sterility Tests. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
  3. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Compound Evidence Institute · CEI-MN-041/3 · https://compoundevidence.com/monographs/thymalin/clinical-evidence/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.